Pharma Change Control
Change
control is a systematically Approach to prevent unwanted, unapproved, and
unintentional changes to validated processes, procedures, methods, equipment,
documents, and facilities. This procedure is applicable to changes/deletion
made to existing or introduction of new document/manufacturing process /
formula / method / facility / equipment / instrument / utilities / layout /
software (used in GMP aspects).The
change proposals are subjected to existing or introduction of the new process,
product, statutory / regulatory / customer requirements
o
Type of Change:
§
Temporary Change Control:
Changes for a specified limited
duration where the change will be approved prior to the change being
implemented with the intention of returning the system to its previous state.
Temporary changes are for a certain time or for a specified number of batches.
Evaluation of impact shall be the same as for permanent changes since the change could have a potential adverse impact even if only a single batch is
produced under the temporary change conditions
Note: Maximum time duration shall not be more than 120
days in case of Temporary Change.
§ Permanent Change Control:
Changes for permanent basis or intended to
permanent to the system. Specified. The changes shall be assessed for risk and
taken approval before the implementation state.
· Changes
which have been assessed under a temporary change and found to be delivering
the desired improvement in Practices / Procedures / Systems / Quality and can
be introduced into the Practices / Procedures / Systems / Quality on a
permanent basis.
·
Note: Introduction of new
product/brand in the facility shall be treated as permanent.
Other things Permanent Change Control classified in sub-category
Ø Minor
change
v A change that does not have any
impact on the quality of the product and operating system.
v Does not alter the process,
significantly.
v Has no impact on regulatory
filings.
Ø Major
change
v A change that has significant
impact on the quality and/or safety of the final product.
v Could shift the process
significantly, affecting the quality yield, stability, impurity profile, etc.
v Additional / changed testing
required and suitable revalidation study to justify the change.
No comments:
Post a Comment
Pharmaceutical guideline only